| scholarly article | Q13442814 |
| P2093 | author name string | Lazaros I Sakkas | |
| Eirini I Rigopoulou | |||
| Maria G Grammatikopoulou | |||
| Dimitrios Petrou Bogdanos | |||
| Konstantinos Gkiouras | |||
| Xenophon Theodoridis | |||
| Eirini Pagkalidou | |||
| Anna G Apostolidou | |||
| Evangelia Chatzikyriakou | |||
| P2860 | cites work | Conducting systematic reviews of diagnostic studies: didactic guidelines | Q24797459 |
| Crohn's disease specific pancreatic antibodies: clinical and pathophysiological challenges | Q26823779 | ||
| QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies | Q27861031 | ||
| Inflammatory bowel disease | Q28275666 | ||
| Uptake through glycoprotein 2 of FimH(+) bacteria by M cells initiates mucosal immune response | Q28506068 | ||
| Empirical evidence of design-related bias in studies of diagnostic tests | Q30776370 | ||
| Performance of methods for meta-analysis of diagnostic test accuracy with few studies or sparse data | Q30977041 | ||
| Identification of GP2, the major zymogen granule membrane glycoprotein, as the autoantigen of pancreatic antibodies in Crohn's disease | Q33473077 | ||
| Value of symptoms and additional diagnostic tests for colorectal cancer in primary care: systematic review and meta-analysis | Q33766347 | ||
| Molecular cloning and sequences of cDNAs encoding alpha (large) and beta (small) isoforms of human pancreatic zymogen granule membrane-associated protein GP2. | Q33897799 | ||
| The diagnostic odds ratio: a single indicator of test performance | Q34276416 | ||
| An overview of systematic reviews of diagnostic tests accuracy | Q34279686 | ||
| Incorporation of the pancreatic membrane protein GP-2 into secretory granules in exocrine but not endocrine cells | Q34290586 | ||
| Pancreatic-specific autoantibodies to glycoprotein 2 mirror disease location and behaviour in younger patients with Crohn's disease. | Q34367414 | ||
| Emerging concepts in non-invasive monitoring of Crohn's disease. | Q55364545 | ||
| Antibodies to GP2, the major zymogen granule membrane glycoprotein, in inflammatory bowel diseases | Q57265325 | ||
| Pancreatic Autoantibodies in Inflammatory Bowel Disease | Q57265453 | ||
| How to Validate Predictive Immunohistochemistry Testing in Pathology?: A Practical Approach Exploiting the Heterogeneity of Programmed Death Ligand-1 Present in Non-Small Cell Lung Cancer | Q57279680 | ||
| Inflammatory bowel disease in children and adolescents: recommendations for diagnosis--the Porto criteria | Q57697872 | ||
| Loss of tolerance to glycoprotein 2 isoforms 1 and 4 is associated with Crohn's disease of the pouch | Q58573712 | ||
| Differentiating Crohn's disease from intestinal tuberculosis | Q61443445 | ||
| Faecal calprotectin to detect inflammatory bowel disease: a systematic review and exploratory meta-analysis of test accuracy | Q64113466 | ||
| A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations | Q74545500 | ||
| An advance notification letter increases participation in colorectal cancer screening | Q80601738 | ||
| Autoantibodies to GP2, the major zymogen granule membrane glycoprotein, in patients with gluten-sensitive enteropathy: a possible serological trap | Q83305625 | ||
| Evidence of Crohn's disease-related anti-glycoprotein 2 antibodies in patients with celiac disease | Q86028278 | ||
| Diagnostic and clinical significance of Crohn's disease-specific pancreatic anti-GP2 and anti-CUZD1 antibodies | Q86095389 | ||
| Nature journals tighten rules on non-financial conflicts | Q87664009 | ||
| Increased IgA glycoprotein-2 specific antibody titres in refractory celiac disease | Q88120101 | ||
| Performance of Baveno VI and Expanded Baveno VI Criteria for Excluding High-Risk Varices in Patients With Chronic Liver Diseases: A Systematic Review and Meta-analysis | Q91942275 | ||
| Inflammatory Bowel Disease Serological Immune Markers Anti-Saccharomyces cerevisiae Mannan Antibodies and Outer Membrane Porin C are Potential Biomarkers for Hirschsprung-associated Enterocolitis | Q92969366 | ||
| Autoantibodies against exocrine pancreas in Crohn's disease are directed against two antigens: the glycoproteins CUZD1 and GP2. | Q34472649 | ||
| Meta-analysis of diagnostic accuracy studies in mental health | Q34497278 | ||
| Glycoprotein 2 antibodies in Crohn's disease. | Q34750329 | ||
| Diagnostic and clinical significance of Crohn's disease-specific anti-MZGP2 pancreatic antibodies by a novel ELISA. | Q35523768 | ||
| Diagnostic Potential of Zymogen Granule Glycoprotein 2 Antibodies as Serologic Biomarkers in Chinese Patients With Crohn Disease | Q36207151 | ||
| Systematic Review and Meta-Analysis of Studies Evaluating Diagnostic Test Accuracy: A Practical Review for Clinical Researchers-Part I. General Guidance and Tips | Q36279829 | ||
| Ileal inflammation may trigger the development of GP2-specific pancreatic autoantibodies in patients with Crohn's disease. | Q36355419 | ||
| European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis | Q36397893 | ||
| Evidence based diagnosis: does the language reflect the theory? | Q36576701 | ||
| The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease | Q37118470 | ||
| Systematic reviews of diagnostic test accuracy | Q37346962 | ||
| Potential model for differential diagnosis between Crohn's disease and primary intestinal lymphoma | Q37411507 | ||
| The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management | Q37814541 | ||
| Glycoprotein 2 (GP2): grabbing the FimH bacteria into M cells for mucosal immunity. | Q37862092 | ||
| Understanding sources of bias in diagnostic accuracy studies | Q38094792 | ||
| ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents | Q38162673 | ||
| Principles of analytic validation of immunohistochemical assays: Guideline from the College of American Pathologists Pathology and Laboratory Quality Center | Q38197280 | ||
| Principles for high-quality, high-value testing | Q38566986 | ||
| 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management | Q38962353 | ||
| Diagnostic value of the antiglycoprotein-2 antibody for Crohn's disease: a PRISMA-compliant systematic review and meta-analysis | Q39364535 | ||
| Autoantibodies to GP2, the major zymogen granule membrane glycoprotein, are new markers in Crohn's disease | Q39613357 | ||
| Comprehensive gene expression profiling of Peyer's patch M cells, villous M-like cells, and intestinal epithelial cells. | Q39975699 | ||
| Autoantibodies Against Glycoprotein 2 Isoforms in Pediatric Patients with Inflammatory Bowel Disease | Q40141872 | ||
| Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology | Q40390478 | ||
| Distinct Anti-IFI16 and Anti-GP2 Antibodies in Inflammatory Bowel Disease and Their Variation with Infliximab Therapy. | Q40578397 | ||
| Rediscovery of the Anti-Pancreatic Antibodies and Evaluation of their Prognostic Value in a Prospective Clinical Cohort of Crohn's Patients: The Importance of Specific Target Antigens [GP2 and CUZD1]. | Q40945601 | ||
| Recommendations for reporting of systematic reviews and meta-analyses of diagnostic test accuracy: a systematic review | Q42373529 | ||
| Serologic Anti-GP2 Antibodies Are Associated with Genetic Polymorphisms, Fibrostenosis, and Need for Surgical Resection in Crohn's Disease | Q42720701 | ||
| Evidence of bias and variation in diagnostic accuracy studies | Q42860877 | ||
| Classification of inflammatory bowel disease | Q44185737 | ||
| Meta-analysis of diagnostic test accuracy assessment studies with varying number of thresholds | Q44767951 | ||
| Noninvasive diagnosis of small bowel Crohn's disease: direct comparison of bowel sonography and magnetic resonance enterography. | Q45288151 | ||
| Pancreatic Autoantibodies Against CUZD1 and GP2 Are Associated with Distinct Clinical Phenotypes of Crohn's Disease. | Q45955692 | ||
| Systematic Review and Meta-Analysis of Diagnostic Accuracy of Serum Refractometry and Brix Refractometry for the Diagnosis of Inadequate Transfer of Passive Immunity in Calves | Q46616958 | ||
| Sensitivity, Specificity, and Predictive Values: Foundations, Pliabilities, and Pitfalls in Research and Practice | Q47110592 | ||
| Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement | Q47555051 | ||
| Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. | Q47758448 | ||
| Comparison of different histological indexes in the assessment of UC activity and their accuracy regarding endoscopic outcomes and faecal calprotectin levels | Q49167036 | ||
| Antibodies against glycoprotein 2 display diagnostic advantages over ASCA in distinguishing CD from intestinal tuberculosis and intestinal Behçet's disease | Q49985633 | ||
| Does industry-sponsored education foster overdiagnosis and overtreatment of depression, osteoporosis and over-active bladder syndrome? An Australian cohort study | Q50351538 | ||
| Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. | Q53153874 | ||
| Diagnostic accuracy of point-of-care natriuretic peptide testing for chronic heart failure in ambulatory care: systematic review and meta-analysis. | Q55041669 | ||
| P433 | issue | 2 | |
| P921 | main subject | inflammatory bowel diseases | Q917447 |
| P304 | page(s) | 246-265 | |
| P577 | publication date | 2020-01-01 | |
| P1433 | published in | World Journal of Gastroenterology | Q15708885 |
| P1476 | title | Diagnostic and clinical significance of antigen-specific pancreatic antibodies in inflammatory bowel diseases: A meta-analysis | |
| P478 | volume | 26 |
| Q90364948 | The search for the Holy Grail: autoantigenic targets in primary sclerosing cholangitis associated with disease phenotype and neoplasia | cites work | P2860 |
Search more.